ICON Acquires Oxford Outcomes
14 Janeiro 2011 - 9:37AM
Business Wire
ICON plc, (NASDAQ:ICLR)(ISIN:IE0005711209), a
global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries, today
announced the expansion of its Late Phase and Outcomes Research
services through the acquisition of Oxford Outcomes, a leading
international health outcomes consultancy. Elizabeth Thiele,
formerly ICON’s Executive Vice President of Business Development,
has been appointed President of this specialised service unit.
Headquartered in Oxford, UK, and with offices in the USA and
Canada, Oxford Outcomes provides specialist services in the areas
of patient reported outcomes (PRO), health economics, epidemiology
and translation and linguistic validation.
Commenting on the acquisition, Peter Gray, CEO at ICON plc,
said, “The biopharmaceutical industry and regulators are more than
ever before using post-marketing studies to demonstrate efficacy
and safety, as well as demonstrating the economic value of
products. Oxford Outcomes has grown to become a leader in its field
and brings to ICON a wealth of expertise in the fields of health
economics, outcomes research and epidemiology and a strong
reputation for excellent client service.”
“We are really excited about joining ICON,” commented Paul
Quarterman, Group Managing Director of Oxford Outcomes. “The demand
for health outcomes services has never been greater and merging
with ICON gives us the opportunity to effectively integrate
clinical development with outcomes research on a global scale.
Blending the knowledge and expertise from both companies will lead
to powerful, market-leading client solutions, both in the
post-marketing arena and earlier in the development process.”
Elizabeth Thiele, President, Late Phase & Outcomes Research,
at ICON commented, “Oxford Outcomes’ demonstrated excellence in
late phase and outcomes research has allowed it to build a blue
chip client base, which includes the world’s top-tier
pharmaceutical, biotechnology and medical device companies. We look
forward to building on these long-standing relationships and to
offering existing ICON clients a more in-depth suite of outcomes
services.”
Fairmount Partners served as financial advisors to Oxford
Outcomes in this transaction.
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has around 7,800 employees, operating from 72 locations in 39
countries.
Further information is available at www.iconplc.com
ICON/ICLR-F
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024